MAPT and Cognitive impairment: Again the threshold EBM stage decreased for increasing follow-up durations, with abnormal CSF total tau, phosphorylated tau and amyloid-β1–42 levels best predicting conversion from cognitively normal to mild cognitive impairment over a period of ≤4 years, but just abnormal CSF total tau and phosphorylated tau best predicting conversion over 5 years.